{
  "docId": "019dd923-622c-750b-8b97-5cb48bf2a635",
  "docSlug": "b8afd3741673",
  "documentTitle": "Chinook Therapeutics Inc (KDNY)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-05-16 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 33,
  "pageCount": 36,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 25,
  "notes": "Poster format including background, baseline/safety data, efficacy results, and conclusions.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "data_table",
    "bar_chart_vertical",
    "process_diagram",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-5cb48bf2a635/33",
  "deckHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.65,
        "y": 0.62
      },
      "kind": "chart",
      "text": "UPCR Cumulative Reduction at Week 12 and 24",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f97664ff-4ab4-4471-af3a-10f5e232bacb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.38,
        "y": 0.62
      },
      "kind": "chart",
      "text": "Proteinuria Reduction in Patients with IgA Nephropathy",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40023413-d24c-47f5-9d91-ccfbbd5741c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.55,
        "y": 0.21
      },
      "kind": "diagram",
      "text": "AFFINITY Study Design",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e48c5007-abb5-4b2e-a389-355c6eb027a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.55,
        "y": 0.78
      },
      "kind": "diagram",
      "text": "Ongoing ALIGN phase 3 trial design",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79e35509-49a4-45fe-a11b-b8c6898fbf72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.15,
        "y": 0.78
      },
      "kind": "list",
      "text": "Conclusions",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "129e9f6e-a3b7-4e40-821e-fa01b8da2c5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "UPCR reduction: 79%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d2-81867a4ef469",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Atrasentan is an investigational drug that has not been approved by regulatory authorities. Efficacy and safety have not been established. There is no guarantee that it will become commercially available for the use(s) under investigation.",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d2-7e0a42ea9ec7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.15,
        "y": 0.42
      },
      "kind": "table",
      "text": "Demographics and Baseline Characteristics",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eee03360-4d49-4c72-b805-fe17f9198549",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.15,
        "y": 0.08
      },
      "kind": "title",
      "text": "Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "391817bc-48da-4b68-ac60-2d6aad225cd9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 33,
      "from": 28,
      "beatId": "640ed796-f0a7-4d27-b017-41863f0ffedf",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The report presents the 'victory' of Muddy Waters Research in uncovering the truth",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 33,
      "from": 28,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6980f318-c257-42fa-96be-f6e3de335b06",
      "evidence": "The report implies that investors and analysts should be cautious",
      "position": 1,
      "objective": "To highlight the consequences of not addressing the issues with the trial results",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}